Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma
Editor Note: For more information about this release, please scroll to bottom.
LONDON, November 24, 2014
Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer
THOUSAND OAKS, Calif., Nov.
Spherix Litigation Against Cisco Continues On Patents Acquired from Rockstar Consortium
BETHESDA, Md., Nov.
Purdue Pharma L.P. Receives FDA Approval for HysinglaTM ER (hydrocodone bitartrate) Extended-Release Tablets CII, A Once-Daily Opioid Analgesic Formulated with Abuse-Deterrent Properties
IMS Health Study Forecasts Global Spending on Medicines to Increase 30 Percent by 2018, to $1.3 Trillion
Global Oncology Market to hit $109 billion - Spotlight on Drug Life Cycle Management, M&A and Pipeline Strategies
LONDON and NEW YORK, November 19, 2014 /PRNewswire/ --
First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults
TITUSVILLE, N.J., Nov.